You are here: Industry Insights > Provention

News List

FDA declines to approve Provention Bio’s teplizumab for diabetes pharmaceutical-technology
July 08, 2021
The US Food and Drug Administration (FDA) has declined to approve Provention Bio’s biologics licence application (BLA) for teplizumab in type 1 diabetes (T1D), an autoimmune disease.
Intravacc Completes Project for Provention Bio’s Vax Candidate contractpharma
January 20, 2021
Contract development and manufacturing organization (CDMO) Intravacc, said that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than 36 months, has entered into a first in ...
Provention Bio Announces Teplizumab BLA for Delay or Prevention of Clinical T1D americanpharmaceuticalreview
January 11, 2021
Provention Bio announced the Biologics License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA).
Provention Announces Positive Data from Lupus Treatment Study americanpharmaceuticalreview
March 19, 2020
Provention Bio announced positive top-line results from the Phase 1b portion of the PREVAIL (PRV-3279 EVAluation In Lupus) study evaluating PRV-3279 in healthy volunteers.
Provention Bio Appoints Clinical Development SVP contractpharma
August 21, 2019
Dr. Kell will lead the PRV-031 program, including the oversight of the Phase III PROTECT study and support of regulatory submissions.
Provention Bio Initiates Trial Evaluating PRV-3279 in Lupus americanpharmaceuticalreview
August 09, 2019
Provention Bio has dosed the first patients in its PREVAIL (PRV-3279 EVAluation In Lupus) study, a Phase 1b/2a clinical trial evaluating PRV-3279. PRV-3279 is a humanized diabody (a bispecific scaffold biologic molecule) targeting the B-cell surface prote
Provention’s PRV-031 found to delay type II diabetes by two years pharmatimes
June 11, 2019
A single course of Provention’s PRV-031 (teplizumab) has been found to delay type I diabetes onset in high-risk individuals by at least two years.
Provention Bio Announces Top-Line Results from its PRV-300 Trial americanpharmaceuticalreview
May 10, 2019
Provention Bio Announces Top-Line Results from its PRV-300 Trial.
Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes drugs
April 17, 2019
Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes.
Janssen deal gives new kid in town Provention two immune candidates fiercebiotech
September 22, 2017
Right on the heels of a $28 million seed financing, Provention Bio has snapped up two inflammatory bowel disease candidates from Janssen that should make it a double clinical-stage biotech next year.